Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ILB® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis.
Lazzarino G, Mangione R, Belli A, Di Pietro V, Nagy Z, Barnes NM, Bruce L, Ropero BM, Persson LI, Manca B, Saab MW, Amorini AM, Tavazzi B, Lazzarino G, Logan A. Lazzarino G, et al. Among authors: nagy z. J Pers Med. 2021 Aug 14;11(8):794. doi: 10.3390/jpm11080794. J Pers Med. 2021. PMID: 34442438 Free PMC article.
ILB®, a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury.
Lazzarino G, Di Pietro V, Rinaudo M, Nagy Z, Barnes NM, Bruce L, Signoretti S, Mangione R, Saab MW, Tavazzi B, Belli A, Lazzarino G, Amorini AM, Logan A. Lazzarino G, et al. Among authors: nagy z. Int J Mol Sci. 2022 Jul 30;23(15):8460. doi: 10.3390/ijms23158460. Int J Mol Sci. 2022. PMID: 35955592 Free PMC article.
The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis.
Logan A, Belli A, Di Pietro V, Tavazzi B, Lazzarino G, Mangione R, Lazzarino G, Morano I, Qureshi O, Bruce L, Barnes NM, Nagy Z. Logan A, et al. Among authors: nagy z. Front Pharmacol. 2022 Aug 30;13:983853. doi: 10.3389/fphar.2022.983853. eCollection 2022. Front Pharmacol. 2022. PMID: 36110516 Free PMC article.
A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.
Srinivasan V, Homer V, Barton D, Clutterbuck-James A, Jenkins S, Potter C, Brock K, Logan A, Smith D, Bruce L, Nagy Z, Bach SP. Srinivasan V, et al. Among authors: nagy z. PLoS One. 2024 Jul 11;19(7):e0291285. doi: 10.1371/journal.pone.0291285. eCollection 2024. PLoS One. 2024. PMID: 38990927 Free PMC article. Clinical Trial.
Insights into eye genetics and recent advances in ocular gene therapy.
Szabó V, Varsányi B, Barboni M, Takács Á, Knézy K, Molnár MJ, Nagy ZZ, György B, Rivolta C. Szabó V, et al. Among authors: nagy zz. Mol Cell Probes. 2025 Jan 11:102008. doi: 10.1016/j.mcp.2025.102008. Online ahead of print. Mol Cell Probes. 2025. PMID: 39805344 Review.
High-efficiency base editing in the retina in primates and human tissues.
Muller A, Sullivan J, Schwarzer W, Wang M, Park-Windhol C, Hasler PW, Janeschitz-Kriegl L, Duman M, Klingler B, Matsell J, Hostettler SM, Galliker P, Hou Y, Balmer P, Virág T, Barrera LA, Young L, Xu Q, Magda DP, Kilin F, Khadka A, Moreau PH, Fellmann L, Azoulay T, Quinodoz M, Karademir D, Leppert J, Fratzl A, Kosche G, Sharma R, Montford J, Cattaneo M, Croyal M, Cronin T, Picelli S, Grison A, Cowan CS, Kusnyerik Á, Anders P, Renner M, Nagy ZZ, Szabó A, Bharti K, Rivolta C, Scholl HPN, Bryson D, Ciaramella G, Roska B, György B. Muller A, et al. Among authors: nagy zz. Nat Med. 2025 Jan 8. doi: 10.1038/s41591-024-03422-8. Online ahead of print. Nat Med. 2025. PMID: 39779923
1,884 results